News briefing: Verastem CMO exits two weeks after joining company; Thermo Fisher inks $550M M&A deal
Two weeks after joining Verastem Oncology as chief medical officer, Frank Neumann is leaving the company for another job.
Neumann had joined Verastem after leaving bluebird bio, which surprisingly split into two companies last week, one in oncology and one in rare diseases. It’s not yet clear to where Neumann is headed next, but he noted in a statement that Verastem’s data and strategy were “truly exciting.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.